Global Biotechnology Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Free Sample Report Free Sample Report Inquire Before Buying Inquire Before Buy Now Buy Now

Global Biotechnology Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

  • Healthcare
  • Apr 2025
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Biotechnology Market

Market Size in USD Billion

CAGR :  % Diagram

Bar chart comparing the Global Biotechnology Market size in 2024 - 1.70 and 2032 - 13.03, highlighting the projected market growth. USD 1.70 Billion USD 13.03 Billion 2024 2032
Diagram Forecast Period
2025 –2032
Diagram Market Size (Base Year)
USD 1.70 Billion
Diagram Market Size (Forecast Year)
USD 13.03 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Biotechnology Market Segmentation, By Product Type (Instruments, Reagents, Services, and Software), Technology (Nano Biotechnology, PCR Technology, DNA Sequencing, Chromatography, Tissue Engineering and Regeneration, Cell-Based Assays, Fermentation, and Others), Application (Bio-pharmacy, Bio-industrial, Bio-services, Bioinformatics, and Bio-agriculture), End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Research Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributors, and Others) - Industry Trends and Forecast to 2032

 Biotechnology Market

Biotechnology Market Size

  • The global biotechnology market was valued at USD 1.70 billion in 2024 and is expected to reach USD 13.03 billion by 2032
  • During the forecast period of 2025 to 2032 the market is likely to grow at a CAGR of 29.00%, primarily driven by advancements in biotechnological research
  • This growth is driven by factors such as AI & machine learning, microbiome research and gene editing & genetic engineering

Biotechnology Market Analysis

  • The biotechnology market refers to the industry focused on the application of biological systems, organisms, and cellular processes to develop products and technologies that improve healthcare, agriculture, and industrial manufacturing. This includes genetic engineering, biopharmaceuticals, synthetic biology, and bio-based innovations aimed at enhancing human health, food security, and environmental sustainability
  • The industry is expanding due to rising investments in R&D, increasing prevalence of chronic diseases, and growing demand for personalized medicine. As biotechnology continues to drive healthcare and industrial transformations, companies are developing targeted therapies, biosimilars, and bio-manufacturing solutions to meet market needs
  • The integration of AI-driven drug discovery, CRISPR gene-editing, and synthetic biology is reshaping the biotechnology landscape by enabling faster drug development, precision medicine, and sustainable alternatives
  • For instance, companies such as Moderna and CRISPR Therapeutics are pioneering mRNA-based vaccines and gene-editing therapies, enhancing treatment efficacy and accessibility
  • The demand for innovative, eco-friendly, and precision-driven biotechnologies will continue to shape the industry, with companies focusing on cutting-edge research, automation, and personalized solutions to maintain a competitive edge

Report Scope and Biotechnology Market Segmentation        

Attributes

Biotechnology Key Market Insights

Segments Covered

  • By Product Type: Instruments, Reagents, Services, and Software
  • By Technology: Nano Biotechnology, PCR Technology, DNA Sequencing, Chromatography, Tissue Engineering and Regeneration, Cell-Based Assays, Fermentation, and Others
  • By Application: Bio-pharmacy, Bio-industrial, Bio-services, Bioinformatics, and Bio-agriculture
  • By End User: Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Academic and Research Institutes, and Others
  • By Distribution Channel: Direct Tender, Third Party Distributors, and Others

Countries Covered

North America

  • U.S.
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • U.K.
  • Netherlands
  • Switzerland
  • Belgium
  • Russia
  • Italy
  • Spain
  • Turkey
  • Rest of Europe

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of Asia-Pacific

Middle East and Africa

  • Saudi Arabia
  • U.A.E.
  • South Africa
  • Egypt
  • Israel
  • Rest of Middle East and Africa

South America

  • Brazil
  • Argentina
  • Rest of South America

Key Market Players

  • Abbott (U.S.)
  • Agilent Technologies (U.S.)
  • Danaher Corporation (U.S.)
  • BD (U.S.)
  • Bio-Rad Laboratories Inc. (U.S.)
  • General Electric Company (U.S.)
  • BIOMÉRIEUX (France)
  • Lonza (Switzerland)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Hoefer, Inc. (U.S.)
  • PerkinElmer Inc. (U.S.)
  • Merck KGaA (Germany)
  • Promega Corporation (U.S.)
  • Quality Biological (U.S.)
  • Siemens (Germany)
  • Bio-Techne (U.S.)
  • TAKARA HOLDINGS INC. (Japan)
  • Sysmex Corporation (Japan)
  • QuidelOrtho Corporation (U.S.)
  • Olympus Corporation (Japan)

Market Opportunities

  • Technological Advancements in Biotechnology

Value Added Data Infosets

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Biotechnology Market Trends

“Rising Expansion of Synthetic Biology for Sustainable Solutions”

  • One prominent trend in the global biotechnology market is the rising expansion of synthetic biology for sustainable solutions
  • This trend is driven by the growing need for eco-friendly and bio-based alternatives, pushing biotechnology companies to develop engineered microbes, lab-grown materials, and bio-manufactured chemicals for various industries
  • For instance, Ginkgo Bioworks and Zymergen are pioneering synthetic biology applications to create sustainable bio-based chemicals, biodegradable plastics, and alternative proteins for industrial and consumer use
  • As industries seek environmentally responsible and resource-efficient solutions, biotech firms are integrating synthetic biology with AI-driven design, automated biofoundries, and precision fermentation to enhance scalability and efficiency
  • This shift is expected to accelerate advancements in bio-manufacturing, ensuring long-term market growth as companies focus on sustainability-driven innovations and scalable production technologies to stay competitive in an evolving industry

Biotechnology Market Dynamics

Driver

“Increasing Prevalence of Chronic Diseases”

  • The increasing prevalence of chronic diseases, including cancer, diabetes, and autoimmune disorders, is significantly driving the demand for effective therapeutic solutions in the biotechnology market
  • As these conditions become more widespread, healthcare providers and patients are seeking innovative treatments that can effectively manage symptoms, enhance quality of life, and improve patient outcomes
  • With healthcare systems prioritizing early diagnosis and targeted treatments, biotechnology companies are developing innovative solutions, including monoclonal antibodies, RNA-based therapies, and CRISPR gene-editing techniques, to improve treatment outcomes and patient care
  • As chronic disease management evolves, biotechnology firms are leveraging advancements in biomanufacturing, biomarker-driven drug development, and next-generation sequencing to enhance therapeutic precision and treatment efficacy
  • Patients and healthcare providers are also emphasizing minimally invasive treatments, biologic drugs, and digital health solutions to ensure better disease monitoring, improved quality of life, and cost-effective healthcare interventions

For instance,

  • Moderna and BioNTech have pioneered mRNA-based therapies, revolutionizing vaccine development and expanding the potential for treating infectious and chronic diseases
  • Novartis and Bluebird Bio are at the forefront of gene and cell therapies, offering breakthrough treatments for genetic disorders and rare diseases
  • With the rising global burden of chronic illnesses and increasing healthcare expenditures, the biotechnology market will continue to experience sustained growth, driving innovation, precision medicine adoption, and the expansion of bio-based therapeutics worldwide

Opportunity

“Technological Advancements in Biotechnology”

  • The rising prevalence of chronic diseases is a key driver of growth in the biotechnology market. As the incidence of conditions such as cancer, diabetes, cardiovascular diseases, and genetic disorders continues to increase, the demand for advanced biopharmaceuticals, gene therapies, and precision medicine solutions is accelerating
  • With healthcare systems prioritizing early diagnosis and targeted treatments, biotechnology companies are developing innovative solutions, including monoclonal antibodies, RNA-based therapies, and CRISPR gene-editing techniques, to improve treatment outcomes and patient care
  • The growing need for personalized and regenerative medicine has led to significant investments in biotechnology R&D, encouraging the development of cell-based therapies, tissue engineering, and AI-driven drug discovery to address the complexities of chronic diseases

For instance,

  • Thermo Fisher Scientific is developing advanced sequencing technologies and laboratory automation tools to accelerate genomic research and drug discovery
  • Twist Bioscience is leveraging DNA synthesis technology to drive innovations in synthetic biology, supporting applications in drug development, agriculture, and industrial biotechnology
  • As biotechnology innovations continue to evolve, companies have the opportunity to develop next-generation therapeutics, eco-friendly bioproducts, and advanced research tools, ensuring continued growth and competitive differentiation in a rapidly advancing market

Restraint/Challenge

“High Research and Development Costs”

  • The high costs associated with research and development (R&D) pose a significant challenge for biotechnology companies. Developing biopharmaceuticals, gene therapies, and synthetic biology solutions requires extensive investment in laboratory infrastructure, clinical trials, and regulatory approvals, making it difficult for smaller firms to compete
  • Rising expenses related to drug discovery, precision medicine, and biologic manufacturing significantly impact overall development costs, leading to higher treatment prices and extended timelines for bringing new therapies to market. Balancing innovation, affordability, and commercial viability remains a key concern for industry players
  • The biotechnology sector also faces financial pressures from regulatory compliance requirements, intellectual property protections, and the cost of obtaining FDA and EMA approvals, which can be lengthy and complex, adding further strain on company budgets

For instance,

  • The average cost of developing a new drug, including clinical trials and regulatory approval, is estimated to exceed USD 2 billion, with success rates remaining low due to stringent safety and efficacy standards
  • As R&D costs continue to rise, the biotechnology industry will continue to face financial and operational challenges, affecting the pace of innovation and the accessibility of advanced biotechnological solutions

Biotechnology Market Scope

The market is segmented on the basis of product type, technology, application, end user, and distribution channel.

Segmentation

Sub-Segmentation

By Product type

  • Instruments
  • Reagents
  • Services
  • Software

By Technology

  • Nano Biotechnology
  • PCR Technology
  • DNA Sequencing
  • Chromatography
  • Tissue Engineering and Regeneration
  • Cell-Based Assays
  • Fermentation
  • Others

By Application

  • Bio-pharmacy
  • Bio-industrial
  • Bio-services
  • Bioinformatics
  • Bio-agriculture

By End user

  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations
  • Academic and Research Institutes
  • Others

By Distribution Channel

  • Direct Tender
  • Third Party Distributors
  • Others

Biotechnology Market Regional Analysis

“North America is the Dominant Region in the Biotechnology Market”

  • North America dominates the biotechnology market, driven by the increasing prevalence of chronic diseases, high healthcare expenditure, and strong investments in research and development. The region’s well-established biopharmaceutical industry, advanced healthcare infrastructure, and supportive regulatory framework further solidify its leadership
  • The U.S. holds a significant share due to rising cases of cancer, diabetes, and cardiovascular diseases which continue to fuel the demand for innovative biotechnological solutions, including gene therapy, precision medicine, and biopharmaceuticals
  • The growing adoption of synthetic biology, AI-driven drug discovery, and CRISPR gene-editing technologies is further shaping the industry in North America, attracting substantial investments from both public and private sectors
  • Key biotechnology companies in the region, such as Amgen, Gilead Sciences, and Moderna, continue to drive innovation through extensive R&D initiatives, expanding their portfolios of biologics, cell therapies, and next-generation biopharmaceuticals

“Asia-Pacific is Projected to Register the Highest Growth Rate”

  • The Asia-Pacific region is expected to witness the highest growth rate in the biotechnology market, driven by expanding biotech enterprises, increasing government support, and rising healthcare needs
  • Countries such as China, India, Japan, and South Korea are emerging as biotechnology hubs, fueled by growing investments in research infrastructure, a rising number of biotech startups, and increased demand for advanced therapeutics
  • The rapid adoption of biosimilars, regenerative medicine, and bio-manufacturing technologies is further accelerating market expansion, with governments actively promoting biotech innovation through funding, regulatory support, and industry partnerships
  • Leading biotechnology firms in the region, such as WuXi Biologics, Biocon, and Takeda Pharmaceuticals, are expanding their capabilities to meet growing global demand, reinforcing Asia-Pacific’s position as a key player in the biotechnology industry

Biotechnology Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

  • Abbott (U.S.)
  • Agilent Technologies (U.S.)
  • Danaher Corporation (U.S.)
  • BD (U.S.)
  • Bio-Rad Laboratories Inc. (U.S.)
  • General Electric Company (U.S.)
  • BIOMÉRIEUX (France)
  • Lonza (Switzerland)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Hoefer, Inc. (U.S.)
  • PerkinElmer Inc. (U.S.)
  • Merck KGaA (Germany)
  • Promega Corporation (U.S.)
  • Quality Biological (U.S.)
  • Siemens (Germany)
  • Bio-Techne (U.S.)
  • TAKARA HOLDINGS INC. (Japan)
  • Sysmex Corporation (Japan)
  • QuidelOrtho Corporation (U.S.)
  • Olympus Corporation (Japan)

Latest Developments in Global Biotechnology Market

  • In October 2023, Gilead Sciences, Inc. partnered with Assembly Biosciences to develop innovative therapeutics targeting severe viral diseases. This collaboration aims to leverage both companies' expertise and resources to accelerate the creation of effective treatment options. By combining their strengths, they seek to address critical unmet medical needs in the field of virology and improve patient outcomes
  • In September 2023, Merck KGaA formed partnerships with BenevolentAI and Exscientia to utilize artificial intelligence in the drug discovery process. This collaboration focuses on developing new treatments in oncology, neurology, and immunology, aiming to identify innovative candidates for clinical development. By harnessing advanced AI technologies, Merck KGaA hopes to accelerate the discovery of groundbreaking therapeutic options
  • In July 2023, Alexion and AstraZeneca Rare Disease entered into an agreement with Pfizer Inc. to acquire preclinical gene therapy programs. This collaboration reinforces their commitment to advancing next-generation genomic medicines by integrating complementary assets and innovative technologies. By pooling resources, the companies aim to accelerate the development of transformative therapies in the field of gene therapy

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The global biotechnology market size was valued at USD 1.70 billion in 2024.
The global biotechnology market is to grow at a CAGR of 29.00% during the forecast period of 2025 to 2032.
The biotechnology market is segmented into five notable segments based on product type, technology, application, end-user, and distribution channel. On the basis of product type, the market is segmented into instruments, reagents, services, and software. On the basis of technology, the market is segmented into nano biotechnology, PCR technology, DNA sequencing, chromatography, tissue engineering and regeneration, cell-based assays, fermentation, and others. On the basis of application, the market is segmented into bio-pharmacy, bio-industrial, bio-services, bioinformatics, and bio-agriculture. On the basis of end-user, the market is segmented into pharmaceutical and biotechnology companies, contract research organizations, academic and research institutes, and others. On the basis of distribution channel, the market is segmented into direct tender, third-party distributors, and others.
Companies such as Abbott (U.S.), Agilent Technologies (U.S.), Danaher Corporation (U.S.), BD (U.S.), Bio-Rad Laboratories Inc. (U.S.), General Electric Company (U.S.), Hoefer, Inc. (U.S.), PerkinElmer Inc. (U.S.), Promega Corporation (U.S.), Quality Biological (U.S.), Bio-Techne (U.S.), and QuidelOrtho Corporation (U.S.); BIOMÉRIEUX (France); Lonza (Switzerland) and F. Hoffmann-La Roche Ltd. (Switzerland); Merck KGaA (Germany) and Siemens (Germany); and TAKARA HOLDINGS INC. (Japan), Sysmex Corporation (Japan), and Olympus Corporation (Japan) are the major companies in the biotechnology market.
The countries covered in the biotechnology market are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Austria, Poland, Norway, Ireland, Hungary, Lithuania, rest of Europe, China, Japan, India, South Korea, Australia, Taiwan, Philippines, Thailand, Malaysia, Vietnam, Indonesia, Singapore, rest of Asia-Pacific, Brazil, Argentina, Chili, Colombia, Peru, Venezuela, Ecuador, Uruguay, Paraguay ,Bolivia, Trinidad And Tobago, Curaçao, rest Of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, rest of Middle East and Africa, Guatemala, Costa Rica, Honduras, EL Salvador, Nicaragua, and rest of Central America.
Testimonial